ERBB2 and breast carcinoma: HER2-low breast cancer may benefit from new therapeutic interventions, such as antibody-drug conjugates (Marchio et al., 2021; Modi et al., 2022; Xin et al., 2022; Zhang et al., 2022; Yang et al., 2023).